Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2

   
Spasov A.A.1, Chepljaeva N.I.1

1. Volgograd State Medical University, Volgograd, Russia
Section: Experimental/Clinical Study
DOI: 10.18097/PBMC20156104488      UDK: 615.272.3: 616.379-008.64      PubMed Id: 26350740
Year: 2015  Volume: 61  Issue: 4  Pages: 488-496
This review summarizes data on the main approaches used for the search of biologically active compounds modulating the level and physiological activity of incretins. Currently two groups of drugs are used in clinical practice: they either replenish the deficit of incretins (glucagon-like peptide-1 receptor agonists) or inhibit the degradation processes (dipeptidyl peptidase 4 inhibitors). In addition, new groups of substances are actively searched. These include non-peptide agonists of glucagon-like peptide-1 receptors, agonists/antagonists of glucose-dependent insulinotropic peptide, the hybrid polypeptides based on glucagon-like peptide-1 and glucagon
Download PDF:
Reference:

Spasov A.A., Chepljaeva N.I. (2015) Biomeditsinskaya khimiya, 61(4), 488-496.
This paper is also available as the English translation:10.1134/S199075081404009X
References  
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)